Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFB-024 in healthy volunteers and Type 2 diabetes
NCT04880291Phase 1Completed
- Sponsor
- Goldfinch Bio
- Start
- May 2021
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GFB-024 in diabetic nephropathy (DN) and type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Goldfinch Bio. Primary endpoint: Safety and tolerability following single ascending doses of GFB-024 at 10 weeks. Started May 2021; status: completed.
02
Drugs
GFB-024
03
Conditions
diabetic nephropathy (DN)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04880291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04880291.